Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LPAR3 | Q9UBY5 | 13/20 | 0.65 |
| ▸ | LPAR2 | Q9HBW0 | 8/20 | 0.65 |
| ▸ | LPAR1 | Q92633 | 6/20 | 0.65 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.50 |
| ▸ | LPAR5 | Q9H1C0 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | ESR1 | P03372 | 1/20 | 0.43 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.43 |
| ▸ | CDC25A | P30304 | 1/20 | 0.43 |
| ▸ | AGTR1 | P30556 | 1/20 | 0.43 |
| ▸ | AKT1 | P31749 | 1/20 | 0.43 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.43 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1123899 | 0.98 | LPAR3 (0.69) | LPAR3LPAR2LPAR1CYP3A4LPAR5 | |
| SCHEMBL6284052 | 0.98 | LPAR3 (0.69) | LPAR3LPAR2LPAR1CYP3A4LPAR5 | |
| SCHEMBL3814362 | 0.98 | LPAR3 (0.69) | LPAR3LPAR2LPAR1CYP3A4LPAR5 | |
| SCHEMBL1123777 | 0.98 | LPAR3 (0.69) | LPAR3LPAR2LPAR1CYP3A4LPAR5 | |
| SCHEMBL10834868 | 0.98 | LPAR3 (0.69) | LPAR3LPAR2LPAR1CYP3A4LPAR5 | |
| SCHEMBL557713 | 0.93 | CYP3A4 (0.58) | LPAR3LPAR2LPAR1CYP3A4 | |
| SCHEMBL3670692 | 0.92 | LPAR3 (0.62) | LPAR3LPAR2LPAR1CYP3A4LPAR5 | |
| SCHEMBL29222525 | 0.92 | LPAR3 (0.62) | LPAR3LPAR2LPAR1CYP3A4LPAR5 | |
| SCHEMBL27854174 | 0.92 | LPAR3 (0.62) | LPAR3LPAR2LPAR1CYP3A4LPAR5 | |
| SCHEMBL2869539 | 0.91 | LPAR3 (0.67) | LPAR3LPAR2LPAR1CYP3A4LPAR5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220153730-A9 | INHIBITORS OF C-JUN-N-TERMINAL KINASE (JNK) | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2022-05-19 | — | — | US | disclosed |
| US-20210300911-A1 | INHIBITORS OF C-JUN-N-TERMINAL KINASE (JNK) | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2021-09-30 | — | — | US | disclosed |
| US-10981903-B2 | Inhibitors of c-Jun-N-terminal kinase (JNK) | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2021-04-20 | — | — | US | disclosed |
| US-20200087295-A9 | INHIBITORS OF C-JUN-N-TERMINAL KINASE (JNK) | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2020-03-19 | — | — | US | disclosed |
| EP-3569598-A1 | INHIBITORS OF C-JUN-N-TERMINAL KINASE (JNK) | Dana Farber Cancer Institute, Inc. (US) | 2019-11-20 | — | — | EP | disclosed |
| US-20190248778-A1 | INHIBITORS OF C-JUN-N-TERMINAL KINASE (JNK) | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2019-08-15 | — | — | US | disclosed |
| EP-2822935-B1 | INHIBITORS OF C-JUN-N-TERMINAL KINASE (JNK) | DANA FARBER CANCER INST INC (US) | 2019-05-15 | — | — | EP | disclosed |
| US-10144730-B2 | Inhibitors of c-Jun-N-terminal kinase (JNK) | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2018-12-04 | — | — | US | disclosed |
| US-20160368910-A1 | INHIBITORS OF C-JUN-N-TERMINAL KINASE (JNK) | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2016-12-22 | — | — | US | disclosed |
| US-9382239-B2 | Inhibitors of c-Jun-N-terminal kinase (JNK) | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2016-07-05 | — | — | US | disclosed |
| EP-2822935-A1 | INHIBITORS OF C-JUN-N-TERMINAL KINASE (JNK) | Dana-Farber Cancer Institute, Inc. (US) | 2015-01-14 | — | — | EP | disclosed |
| US-20140309249-A1 | INHIBITORS OF C-JUN-N-TERMINAL KINASE (JNK) | Dana-Farber Cancer Intitute, Inc. (US) | 2014-10-16 | — | — | US | disclosed |
| WO-2013074986-A1 | INHIBITORS OF C-JUN-N-TERMINAL KINASE (JNK) | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2013-05-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10981903-B2 | Inhibitors of c-Jun-N-terminal kinase (JNK) | CNKSR1, MAPK1, MAP3K1 | LPAR3 3257/4885LPAR2 2555/4885LPAR1 2047/4885 |
| US-20210300911-A1 | INHIBITORS OF C-JUN-N-TERMINAL KINASE (JNK) | CNKSR1, MAPK1, MAP3K1 | LPAR3 3257/4885LPAR2 2555/4885LPAR1 2047/4885 |
| US-20200087295-A9 | INHIBITORS OF C-JUN-N-TERMINAL KINASE (JNK) | CNKSR1, MAPK1, MAP3K1 | LPAR3 3257/4885LPAR2 2555/4885LPAR1 2047/4885 |
| US-20220153730-A9 | INHIBITORS OF C-JUN-N-TERMINAL KINASE (JNK) | CNKSR1, MAPK1, MAP3K1 | LPAR3 3257/4885LPAR2 2555/4885LPAR1 2047/4885 |
| US-20160368910-A1 | INHIBITORS OF C-JUN-N-TERMINAL KINASE (JNK) | CNKSR1, MAPK1, MAP3K1 | LPAR3 3257/4885LPAR2 2555/4885LPAR1 2047/4885 |
| US-20140309249-A1 | INHIBITORS OF C-JUN-N-TERMINAL KINASE (JNK) | CNKSR1, MAPK1, MAP3K1 | LPAR3 3257/4885LPAR2 2555/4885LPAR1 2047/4885 |
| US-20190248778-A1 | INHIBITORS OF C-JUN-N-TERMINAL KINASE (JNK) | CNKSR1, MAPK1, MAP3K1 | LPAR3 3257/4885LPAR2 2555/4885LPAR1 2047/4885 |
| US-10144730-B2 | Inhibitors of c-Jun-N-terminal kinase (JNK) | CNKSR1, MAPK1, MAP3K1 | LPAR3 3257/4885LPAR2 2555/4885LPAR1 2047/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.